In a landmark decision, New Zealand has officially approved the medical use of psilocybin — the active compound found in magic mushrooms — for the treatment of individuals suffering from treatment-resistant depression. The announcement was made by the country’s Medicines Control Agency on Tuesday, marking a major policy shift in mental health treatment.
The approval allows authorized psychiatrists to prescribe psilocybin in controlled clinical settings, but only for patients who have not responded to traditional forms of therapy or medication. The substance, long classified as a prohibited drug, will now be reclassified for restricted medical use under strict regulatory supervision.
Health Minister Dr. Ayesha Verma welcomed the move, citing growing global evidence supporting the use of psychedelic compounds in psychiatric care. “This decision reflects our commitment to advancing mental health treatment based on scientific evidence. For patients who have exhausted all conventional options, psilocybin offers new hope,” Dr. Verma said.
The decision follows several international clinical trials and studies, including a recent one published in The Lancet Psychiatry, which found that psilocybin-assisted therapy significantly reduced symptoms of major depression in patients who had not responded to other treatments. The effects of just one or two guided sessions were shown to last for several months.
Mental health professionals in New Zealand have largely welcomed the development. Dr. Michael Tan, a psychiatrist involved in psychedelic research, said the move could be life-changing for thousands of patients. “Psilocybin is not a miracle drug, but when used responsibly in a therapeutic setting, it has shown the potential to reset the brain’s depressive patterns,” he explained.
To ensure safe and ethical implementation, the Ministry of Health has issued comprehensive guidelines. These include mandatory training and certification for clinicians, pre-screening of patients, and post-treatment monitoring. A new national training program in psychedelic-assisted therapy will also be launched in collaboration with the University of Auckland and the Royal New Zealand College of Psychiatrists.
However, the decision has sparked mixed reactions from some conservative groups and healthcare advocates, who expressed concerns about the long-term effects and risks of dependency or misuse. In response, officials emphasized that the therapy would be tightly regulated and accessible only to a small, high-need patient group.
New Zealand now joins countries like Australia, Canada, and parts of the United States in exploring the therapeutic potential of psychedelics. Advocates believe this move could pave the way for broader adoption of similar treatments in the future, particularly as rates of depression and mental health conditions continue to rise.
With this historic approval, New Zealand is positioning itself at the forefront of progressive, evidence-based approaches to mental healthcare — offering new hope for those most in need.
